Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Jul 2, 2025 08:08PM
Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations Jun 19, 2025 06:08AM
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer Mar 20, 2025 06:00AM
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application Jan 7, 2025 05:00AM
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer Dec 11, 2024 05:05AM


Dec 9, 2024 05:00AM Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
Nov 8, 2024 05:01AM Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Oct 13, 2024 04:04AM Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Sep 17, 2024 03:47AM Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characte
Jun 19, 2024 07:30AM Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Jun 2, 2024 06:18AM Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 24, 2024 04:32AM Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Apr 24, 2024 10:10AM Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Apr 7, 2024 07:09AM FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Dec 13, 2023 05:00AM Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
Dec 12, 2023 05:00AM Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH
Dec 10, 2023 05:00AM Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
Sep 21, 2023 08:26AM Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL
Sep 14, 2023 05:07AM Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
Sep 10, 2023 05:03AM Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology
Aug 23, 2023 07:21AM Dizal's Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations
Aug 17, 2023 05:10AM 2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with
Jun 7, 2023 04:45AM Dizal Leads China's Biotech Innovation by Showcasing Strength of its Oncology Pipeline at 2023 ASCO
May 25, 2023 06:00PM Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting